ACV meeting statement, Meeting 40, 18 January 2023

Section A: Submissions for registration

The committee provided advice on one submission:

• Provisional registration of new vaccine Comirnaty Original / Omicron BA.4-5, containing tozinameran and famtozinameran, to prevent COVID-19 (sponsor Pfizer Australia Pty Ltd).

Details of the ACV advice associated with premarket items has been or will be released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see AusPAR search.

Section B: Safety

The committee was not asked to provide advice on any safety matter.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines

or contact the ACV by email ACV@health.gov.au.